Inhibitory effect of gefitinib and lapatinib on proliferation of HEL cells.
- Author:
Xiang-Meng HE
1
;
Ling-Yan ZHANG
;
Ying LI
Author Information
1. Shandong Medical Imaging Research Institute, Jinan, Shandong Province, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
pharmacology;
Cell Line, Tumor;
Cell Proliferation;
drug effects;
Humans;
Janus Kinase 2;
genetics;
Mutation;
Myeloproliferative Disorders;
metabolism;
pathology;
Protein Kinase Inhibitors;
pharmacology;
Quinazolines;
pharmacology
- From:
Journal of Experimental Hematology
2012;20(2):372-375
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the therapeutic effect of two molecular targeted therapeutic drugs, tyrosine kinase inhibitors gefitinib and lapatinib, on JAK2 V617F positive myeloproliferative disorders (MPD). The human leukemia cell line (HEL cell line) carrying JAK2 V617F mutation was treated with gefitinib (0.5, 1, 5, 10, 25 µmol/L) and lapatinib (0.5, 1, 2, 4, 8, 16 µmol/L) respectively. MTT method was used to detect HEL cell proliferation. The apoptotic rate and cell cycle were measured by flow cytometry. The results showed that gefitinib could significantly inhibit the proliferation of HEL cells in a dose-dependent manner, it's correlation coefficients for 24 and 48 h were 0.991 and 0.895 respectively. IC(50) at 48 h was 5.4 µmol/L. Gefitinib could effectively induce apoptosis of HEL cells in a dose-dependent manner (r = 0.896). Otherwise, gefitinib could arrest HEL cells at G(0)/G(1) phase. The inhibitory effect of lapatinib was less than gefitinib, it's IC(50) of inhibiting proliferation of HEL cells was 19.6 µmol/L. It is concluded that both gefitinib and lapatinib can inhibit the proliferation of HEL cells. These two tyrosine kinase inhibitors can be used for researching of targeted therapy of JAK2 V617 positive MPD.
